

# Elevated BUN After Chemotherapy

M. Katherine Tolbert, DVM, PhD,  
DACVIM (SAIM)  
Texas A&M University



Romeo, an 11-year-old, 11.6-lb (5.3-kg), neutered male crossbreed dog, was presented for a recheck evaluation for urinary bladder transitional cell carcinoma. He had previously undergone chemotherapy (mitoxantrone [5 mg/m<sup>2</sup> IV q3wk]) for 4 months and definitive radiation therapy.

Romeo had a history of left cranial cruciate ligament rupture that had been conservatively and nonsurgically managed with deracoxib (1.4 mg/kg PO q24h) for the year prior to presentation for a bladder tumor; CBC and serum chemistry profile performed about a month between each visit were unremarkable (*Table*, next page). His owners reported no problems, and he had a normal appetite with no history of vomiting or diarrhea.

## Physical Examination

On physical examination, Romeo was bright, alert, and responsive. The only remarkable findings were left pelvic limb lameness and medial buttress of the left stifle. No abnormalities were noted on fundic examination, no pain was elicited on abdominal palpation, and rectal examination was unremarkable, with normal stool consistency and color.

## Diagnostic Findings

An increase in BUN and BUN:creatinine ratio levels was observed over ≈5 months prior to presentation for recheck evaluation. Because Romeo was able to tolerate deracoxib and had no outwardly detectable adverse effects from NSAID administration, his increased BUN was initially attributed to GI injury secondary to chemotherapy and radiation therapy, but no improvement was shown with omeprazole and sucralfate treatment following chemotherapy. Deracoxib was continued because of the severity of Romeo's orthopedic disease and potential benefits of cyclooxygenase-2 inhibition in

the treatment of bladder carcinomas. Although Romeo was clinically healthy, his BUN levels continued to increase following cessation of radiation therapy and during the weeks in which chemotherapy was not administered. He was treated with sucralfate slurry (500 mg PO q8h) and omeprazole (1 mg/kg PO q12h) for 2 weeks, and CBC and serum chemistry profile were evaluated at regular

intervals; however, his BUN and BUN:creatinine levels continued to increase. A video capsule endoscopy (VCE) was performed to investigate the possibility of subclinical GI bleeding and revealed multiple hemorrhages in the distal small intestine (*Figure*; see *Treatment at a Glance*). Treatment with deracoxib was discontinued after VCE was performed.

## TABLE

### SERUM CHEMISTRY RESULTS DURING DERACOXIB MONOTHERAPY & CHEMOTHERAPY & FOLLOWING RADIATION THERAPY

Parameter	Reference Range	First Biannual Examination	Second Biannual Examination	Before Chemotherapy	After Chemotherapy	After Radiation Therapy	First PPI Therapy	Second PPI Therapy	Discontinuation of Deracoxib
Packed cell volume (%)	39-58	44	47	40	44	47	47	44	47
Platelet count ( $\times 10^3/\mu\text{L}$ )	190-468	374	348	335	389	363	408	429	412
BUN (mg/dL)	6-26	18	17	17	33	39	41	59	26
Creatinine (mg/dL)	0.7-1.5	0.6	0.6	0.7	0.7	0.8	0.7	0.8	0.7
Phosphorous (mg/dL)	2.5-5.6	2.4	3.1	3.1	4	3.1	3.9	3.9	3.1
Calcium (mg/dL)	9.4-11.4	9.4	9.2	9.3	10	10.5	10.4	10.2	9.1
Total protein (g/dL)	5.2-7.3	5.5	5.7	5.7	5.9	6.4	6.1	6.2	6.1
Albumin (g/dL)	3-3.9	3.5	3.1	3.1	3.5	3.7	3.8	3.3	3.2
Sodium (mEq/L)	140-156	148	147	147	151	150	150	148	145
Potassium (mEq/L)	4-5.3	4	4.1	4.1	4.6	4.1	4.5	5	4.8
Chloride (mEq/L)	108-122	112	111	111	112	108	111	111	112

VCE has been used in dogs with unexplained causes of microcytosis, iron-deficiency anemia, or hypoalbuminemia to determine whether the cause was related to GI bleeding.<sup>1</sup> VCE should be reserved for dogs weighing >9.5 lb (4.3 kg) because the size of the capsule restricts its use in smaller dogs. VCE is not recommended in cats, even those weighing >9 lb (4 kg), because of gastric retention of the capsule. The sensitivity of VCE for detection of the source of GI bleeding in dogs is unknown but is likely less than that of traditional endoscopy; thus, VCE should only be used when more sensitive measures for detection of GI bleeding are unavailable.

## DIAGNOSIS: SUBCLINICAL GI BLEEDING

### Treatment & Long-Term Management

Omeprazole and sucralfate were continued; deracoxib was discontinued, and subsequent blood work revealed normalization of Romeo's BUN and serum BUN:creatinine levels. Mitoxantrone therapy was continued for the next year, and his BUN and BUN:creatinine levels remained within normal limits.

### Prognosis & Outcome

At the 6-month follow-up after deracoxib was discontinued, Romeo had no evidence of GI bleeding and was still undergoing chemotherapy treatment for his bladder tumor. Because the GI bleeding was identified early and deracoxib was withdrawn, a good resolution is expected for Romeo's NSAID-induced adverse effects.

## Discussion

Adverse GI effects (eg, vomiting, diarrhea) are relatively common with NSAID administration in dogs, but less common adverse effects (eg, GI bleeding) may not always be detectable by the owner. Patients with multiple risk factors (eg, older dogs, dogs with comorbidities) are likely at increased risk. Early detection and treatment and, when possible, discontinuation of the NSAID can help ensure a good prognosis in dogs with NSAID-induced GI adverse effects (see *Take-Home Messages*, next page).

Continues ►

## TREATMENT AT A GLANCE

- ▶ VCE is a noninvasive tool that can help confirm GI bleeding in dogs if traditional endoscopy is not available or if the dog is not a good anesthetic candidate.<sup>2</sup>
- ▶ Fecal occult blood testing can increase the index of suspicion for GI bleeding in dogs but, because of associated low specificity, should not be used as a stand-alone test.
- ▶ The treatment of choice for NSAID-induced upper GI bleeding is proton-pump inhibitor (PPI; eg, omeprazole, esomeprazole, pantoprazole) therapy at 1 mg/kg PO or IV q12h.<sup>3</sup> This class of drugs is superior to H<sub>2</sub>-receptor antagonists (eg, famotidine, ranitidine) at equivalent doses in the treatment of GI ulceration in dogs.<sup>3</sup>

PPI = proton-pump inhibitor

VCE = video capsule endoscopy



▲ **FIGURE** VCE confirming GI bleeding from multiple hemorrhagic areas (*arrows*) identified in the small intestinal mucosa

## TAKE-HOME MESSAGES

- The most common NSAID-induced adverse effects in dogs are GI in origin.<sup>4</sup>
- Outwardly detectable adverse effects are not always present in dogs with NSAID-induced GI bleeding. Increased BUN and BUN:creatinine levels can be early indicators of subclinical GI bleeding and can occur in the absence of anemia.<sup>5</sup>
- Patients with multiple risk factors (eg, older dogs, dogs receiving ulcerogenic or erosive drugs, dogs with GI comorbidities such as inflammatory bowel disease) are at the highest risk for NSAID-induced GI bleeding.<sup>6</sup> Dogs without other risk factors for GI bleeding that receive NSAIDs at appropriate doses, especially when used for short periods of time, rarely experience adverse effects.<sup>4</sup> In the absence of additional risk factors for NSAID-induced GI injury, NSAIDs should be used alone. In the absence of other risk factors for GI bleeding, prophylactic PPI therapy with NSAID administration is not recommended because, although PPIs can help control GI bleeding in the stomach and proximal duodenum, the combination of NSAIDs with PPIs may worsen distal intestinal bleeding. This is thought to be secondary to alteration of the intestinal microbiota, increased intestinal permeability, and increased intestinal inflammation.<sup>3,7</sup>
- Discontinuation of NSAIDs and treatment with PPIs are recommended when possible for dogs presented with NSAID-induced clinical GI bleeding. ■

## References

1. Mabry K, Hill T, Marks SL, Hardy BT. Use of video capsule endoscopy to identify gastrointestinal lesions in dogs with microcytosis or gastrointestinal hemorrhage [published online August 5, 2019]. *J Vet Intern Med*. doi:10.1111/jvim.15584
2. Davignon DL, Lee AC, Johnston AN, Bowman DD, Simpson KW. Evaluation of capsule endoscopy to detect mucosal lesions associated with gastrointestinal bleeding in dogs. *J Small Anim Pract*. 2016;57(3):148-158.
3. Marks SL, Kook PH, Papich MG, Tolbert MK, Willard MD. ACVIM consensus statement: support for rational administration of gastrointestinal protectants to dogs and cats. *J Vet Intern Med*. 2018;32(6):1823-1840.
4. Monteiro-Steagall BP, Steagall PV, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. *J Vet Intern Med*. 2013;27(5):1011-1019.
5. Prause LC, Grauer GF. Association of gastrointestinal hemorrhage with increased blood urea nitrogen and BUN/creatinine ratio in dogs: a literature review and retrospective study. *Vet Clin Pathol*. 1998;27(4):107-111.
6. Eichstadt LR, Moore GE, Childress MO. Risk factors for treatment-related adverse events in cancer-bearing dogs receiving piroxicam. *Vet Comp Oncol*. 2017;15(4):1346-1353.
7. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. *Gastroenterology*. 2011;141(4):1314-1322, 1322.e1-5.

PPI = proton-pump inhibitor

entyce®

(capromorelin oral solution)

30 mg/mL

**BRIEF SUMMARY:** Before using this product, please consult the full product insert for more information.

**For oral use in dogs only**

**Appetite Stimulant**

**Caution:** Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

**Description:** ENTyce® (capromorelin oral solution) is a selective ghrelin receptor agonist that binds to receptors and affects signaling in the hypothalamus to cause appetite stimulation and binds to the growth hormone secretagogue receptor in the pituitary gland to increase growth hormone secretion.

**Indication:** ENTyce (capromorelin oral solution) is indicated for appetite stimulation in dogs.

**Contraindications:** ENTyce should not be used in dogs that have a hypersensitivity to capromorelin.

**Warnings:** Not for use in humans. Keep this and all medications out of reach of children and pets. Consult a physician in case of accidental ingestion by humans. **For use in dogs only**

**Precautions:** Use with caution in dogs with hepatic dysfunction. ENTyce is metabolized by CYP3A4 and CYP3A5 enzymes (See Clinical Pharmacology). Use with caution in dogs with renal insufficiency. ENTyce is excreted approximately 37% in urine and 62% in feces (See Adverse Reactions and Clinical Pharmacology).

The safe use of ENTyce has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

**Adverse Reactions:** Field safety was evaluated in 244 dogs. The most common adverse reactions were diarrhea and vomiting. Of the dogs that received ENTyce (n = 171), 12 experienced diarrhea and 11 experienced vomiting. Of the dogs treated with placebo (n = 73), 5 experienced diarrhea and 4 experienced vomiting.

To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, call Aratana Therapeutics at 1-844-640-5500.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/AnimalVeterinary/SafetyHealth>

NADA 141-457. Approved by FDA

US Patent: 6,673,929

US Patent: 9,700,591

Made in Canada

**ARATANA**  
THERAPEUTICS®

Manufactured for:  
Aratana Therapeutics, Inc.  
Leawood, KS 66211

ENTyce is a trademark of Aratana Therapeutics, Inc.  
© Aratana Therapeutics, Inc.

AT2-051-1

February 2018